Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult

World Journal of Gastroenterology

Volumn 18, Issue 39, 2012, Pages 5495-5503

  Ito, Tetsuhide ^a   Cadiot, Guillaume ^b   Jensen, Robert T ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b SERVICE DE DERMATOLOGIE   (France)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Gastrin; Gastrinoma; Hypergastrinemia; Neuroendocrine tumor; Secretin test; Serum gastrin; Zollinger Ellison syndrome

Indexed keywords

CHROMOGRANIN A; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; SOMATOSTATIN RECEPTOR;

ACHLORHYDRIA; ATROPHIC GASTRITIS; ESOPHAGUS STENOSIS; GASTRIN BLOOD LEVEL; GASTROINTESTINAL ENDOSCOPY; HUMAN; HYPERGASTRINEMIA; INTESTINE PERFORATION; RADIOIMMUNOASSAY; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH ACID; STOMACH JUICE; STOMACH PH; ZOLLINGER ELLISON SYNDROME;

EID: 84873333695     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i39.5495     Document Type: Review

References (110)

1. Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012; 10: 199-202
2. Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011; 140: 1444-1453
3. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O'Connor JM, Pauwels S, Kloppel G. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182
4. Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009; 46: 13-106
5. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004; 6: 454-463
6. Mignon M, Jais P, Cadiot G. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, editors. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel, Switzerland: S. Karger, 1995: 223-239
7. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492
8. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep 2009; 11: 433-441
9. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT. NANETS treatment guidelines: welldifferentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 735-752
10. Murugesan SV, Varro A, Pritchard DM. Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009; 29: 1055-1068
11. Roy PK, Venzon DJ, Feigenbaum KM, Koviack PD, Bashir S, Ojeaburu JV, Gibril F, Jensen RT. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001; 80: 189-222
12. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119
13. Jensen RT. Zollinger-Ellison syndrome. In: Doherty GM, Skogseid B, editors. Surgical Endocrinology: Clinical Syndromes. Philadelphia: Lippincott Williams and Wilkins, 2001: 291-344
14. Metz DC. Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2012; 10: 126-130
15. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134: 1842-1860
16. Cherner JA, Jensen RT, Dubois A, O'Dorisio TM, Gardner JD, Metcalfe DD. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988; 95: 657-667
17. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14: 579-623
18. Oh DS, Wang HS, Ohning GV, Pisegna JR. Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2006; 4: 1467-1473
19. Corleto VD, Annibale B, Gibril F, Angeletti S, Serrano J, Venzon DJ, Delle Fave G, Jensen RT. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001; 15: 1555-1561
20. McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology 1985; 88: 939-944
21. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-276
22. Banasch M, Schmitz F. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 2007; 119: 573-578
23. Wong H, Yau T, Chan P, Ng IO, Chan G, Hui P, Law WL, Lo CM, Hedley AJ, Epstein RJ. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res 2010; 16: 87-91
24. Sanduleanu S, De Bruïne A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, Lundqvist G, Stockbrügger RW. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802-811
25. Lamberts R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 39: 126-135
26. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, De Bruijne JW, Festen HP, Snel P, Lückers AE, Biemond I, Lamers CB. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99: 621-628
27. Raines D, Chester M, Diebold AE, Mamikunian P, Anthony CT, Mamikunian G, Woltering EA. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 2012; 41: 508-511
28. Arnold R. Diagnosis and differential diagnosis of hypergastrinemia. Wien Klin Wochenschr 2007; 119: 564-569
29. Cadiot G, Hélie C, Vallot T, Marmuse JP, Cosnes J, Riché A, Mignon M. Stenosing esophagitis in Zollinger-Ellison syndrome. Gastroenterol Clin Biol 1994; 18: 1018-1020
30. Hoffmann KM, Gibril F, Entsuah LK, Serrano J, Jensen RT. Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J Clin Endocrinol Metab 2006; 91: 204-212
31. Bondeson AG, Bondeson L, Thompson NW. Stricture and perforation of the esophagus: overlooked threats in the Zollinger-Ellison syndrome. World J Surg 1990; 14: 361-363; discussion 363-364
32. Miller LS, Doppman J, Maton PN, Gardner JD, Jensen RT. Zollinger-Ellison syndrome. Advances in diagnosis and treatment. Handbk Exp Pharmacol 1991; 99: 349-400
33. Waxman I, Gardner JD, Jensen RT, Maton PN. Peptic ulcer perforation as the presentation of Zollinger-Ellison syndrome. Dig Dis Sci 1991; 36: 19-24
34. Scaglia E, Brixi-Benmansour H, Lubrano D, Devulder F, Thiéfin G, Cadiot G. [Duodenal perforation during a secretin test]. Gastroenterol Clin Biol 2008; 32: 375-377
35. Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79: 379-411
36. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005; 3: 39-48
37. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-610
38. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83: 43-83
39. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85: 295-330
40. Borch K, Renvall H, Liedberg G, Andersen BN. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986; 21: 357-363
41. Vannella L, Sbrozzi-Vanni A, Lahner E, Bordi C, Pilozzi E, Corleto VD, Osborn JF, Delle Fave G, Annibale B. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 1361-1369
42. Delle Fave G, Marignani M, Moretti A, D'Ambra G, Martino G, Annibale B. Hypergastrinemia and enterochromaffinlike cell hyperplasia. Yale J Biol Med 1998; 71: 291-301
43. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198-202
44. Brandsborg M, Elsborg L, Andersen D, Brandsborg O, Bastrup-Madsen P. Gastrin concentrations in serum and gastric mucosa in patients with pernicious anaemia. Scand J Gastroenterol 1977; 12: 537-541
45. Agréus L, Storskrubb T, Aro P, Ronkainen J, Talley NJ, Sipponen P. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009; 44: 564-570
46. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999; 13: 49-57
47. Dhillo WS, Jayasena CN, Lewis CJ, Martin NM, Tang KC, Meeran K, Todd JF. Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists. Ann Clin Biochem 2006; 43: 153-155
48. Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN, Vinayek R, Gardner JD, Jensen RT. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989; 111: 713-722
49. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85: 331-364
50. Maton PN, Lack EE, Collen MJ, Cornelius MJ, David E, Gardner JD, Jensen RT. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990; 99: 943-950
51. Berna MJ, Annibale B, Marignani M, Luong TV, Corleto V, Pace A, Ito T, Liewehr D, Venzon DJ, Delle Fave G, Bordi C, Jensen RT. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008; 93: 1582-1591
52. Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle Fave G, Bordi C, Jensen RT. Effect of chronic hypergastrinemia on human enterochromaffinlike cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002; 123: 68-85
53. Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 1999; 85: 1470-1483
54. Abou-Saif A, Gibril F, Ojeaburu JV, Bashir S, Entsuah LK, Asgharian B, Jensen RT. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 2003; 98: 249-261
55. Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993; 32: 161-165
56. Ito T, Igarashi H, Jensen RT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012; 41: 505-507
57. Pregun I, Herszényi L, Juhász M, Miheller P, Hritz I, Patócs A, Rácz K, Tulassay Z. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84: 22-28
58. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-2443
59. Bashir S, Gibril F, Ojeaburu JV, Asgharian B, Entsuah LK, Ferraro G, Crafa P, Bordi C, Jensen RT. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther 2002; 16: 1367-1382
60. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-1649
61. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-630
62. Sato M, Kihara M, Nishitani A, Murao K, Kobayashi S, Miyauchi A, Takahara J. Large and asymptomatic pancreatic islet cell tumor in a patient with multiple endocrine neoplasia type 1. Endocrine 2000; 13: 263-266
63. Hayashi M, Floyd JC, Pek S, Fajans SS. Insulin, proinsulin, glucagon and gastrin in pancreatic tumors and in plasma of patients with organic hyperinsulinism. J Clin Endocrinol Metab 1977; 44: 681-694
64. Liu TH, Tseng HC, Zhu Y, Zhong SX, Chen J, Cui QC. Insulinoma. An immunocytochemical and morphologic analysis of 95 cases. Cancer 1985; 56: 1420-1429
65. Yamaguchi K, Enjoji M. Endocrine neoplasms of the pancreas: a clinicopathologic study of 24 cases and immunohistochemical remarks. Surg Today 1992; 22: 305-312
66. Gurevich L, Kazantseva I, Isakov VA, Korsakova N, Egorov A, Kubishkin V, Bulgakov G. The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract. Cancer 2003; 98: 1967-1976
67. Heitz PU, Kasper M, Polak JM, Kloppel G. Pancreatic endocrine tumors. Hum Pathol 1982; 13: 263-271
68. Mukai K, Grotting JC, Greider MH, Rosai J. Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method. Am J Surg Pathol 1982; 6: 387-399
69. Tomita T. Immunocytochemical staining for islet amyloid polypeptide in pancreatic endocrine tumors. Islets 2011; 3: 344-351
70. Alexander HR, Fraker DL, Norton JA, Bartlett DL, Tio L, Benjamin SB, Doppman JL, Goebel SU, Serrano J, Gibril F, Jensen RT. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238
71. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773
72. Thom AK, Norton JA, Axiotis CA, Jensen RT. Location, incidence, and malignant potential of duodenal gastrinomas. Surgery 1991; 110: 1086-1091; discussion 1091-1093
73. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis 2004; 36 Suppl 1: S106-S120
74. Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C, Ruszniewski P, Le Guludec D, Mignon M. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology 1996; 111: 845-854
75. Ruszniewski P, Amouyal P, Amouyal G, Grangé JD, Mignon M, Bouché O, Bernades P. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629-635
76. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004; 239: 617-625; discussion 626
77. Krudy AG, Doppman JL, Jensen RT, Norton JA, Collen MJ, Shawker TH, Gardner JD, McArthur K, Gorden P. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography, and venous sampling. AJR Am J Roentgenol 1984; 143: 585-589
78. Berna MJ, Jensen RT. Uses of radiolabeled somatostatin receptor analogues in diagnosis of gastrointestinal neuroendocrine tumors. In: Modlin IM, Oberg K. A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Hanover: Felsenstein CCCP, 2007: 328-339
79. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE, Jensen RT. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335-347
80. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731
81. Lebtahi R, Cadiot G, Marmuse JP, Vissuzaine C, Petegnief Y, Courillon-Mallet A, Cattan D, Mignon M, Le Guludec D. False-positive somatostatin receptor scintigraphy due to an accessory spleen. J Nucl Med 1997; 38: 1979-1981
82. Shibata C, Funayama Y, Fukushima K, Ueno T, Kohyama A, Satoh K, Shimosegawa T, Yamagiwa T, Sasaki I. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg 2008; 12: 344-349
83. Jensen RT, Gardner JD, Raufman JP, Pandol SJ, Doppman JL, Collen MJ. Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med 1983; 98: 59-75
84. Goldman JA, Blanton WP, Hay DW, Wolfe MM. False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009; 7: 600-602
85. Feldman M, Schiller LR, Walsh JH, Fordtran JS, Richardson CT. Positive intravenous secretin test in patients with achlorhydria-related hypergastrinemia. Gastroenterology 1987; 93: 59-62
86. Yanda RJ, Ostroff JW, Ashbaugh CD, Guis MS, Goldberg HI. Zollinger-Ellison syndrome in a patient with normal screening gastrin level. Dig Dis Sci 1989; 34: 1929-1932
87. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD. The Pancreas: Biology, Pathobiology and Disease. 2nd ed. New York: Raven Press Publishing Co., 1993: 931-978
88. Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, Venzon DJ, Metz DC, Jensen RT. Assessment and prediction of longterm cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med 1993; 119: 199-206
89. Wolfe MM, Jain DK, Edgerton JR. Zollinger-Ellison syndrome associated with persistently normal fasting serum gastrin concentrations. Ann Intern Med 1985; 103: 215-217
90. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488
91. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, Marx SJ, Gibril F, Jensen RT. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 2008; 247: 501-510
92. Norton JA, Cornelius MJ, Doppman JL, Maton PN, Gardner JD, Jensen RT. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987; 102: 958-966
93. Ruszniewski P, Laucournet H, Elouaer-Blanc L, Mignon M, Bonfils S. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas 1988; 3: 145-152
94. Cryer PE, Hill GJ II. Pancreatic islet cell carcinoma with hypercalcemia and hypergastrinemia: response to streptozotocin. Cancer 1976; 38: 2217-2221
95. Sato T, Konishi K, Kimura H, Maeda K, Yabushita K, Tsuji M, Demachi H, Miwa A. Strategy for pancreatic endocrine tumors. Hepatogastroenterology 2000; 47: 537-539
96. von Schrenck T, Howard JM, Doppman JL, Norton JA, Maton PN, Smith FP, Vinayek R, Frucht H, Wank SA, Gardner JD. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988; 94: 1326-1334
97. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 4-19
98. Gibril F, Lindeman RJ, Abou-Saif A, Shojamanesh H, Roy PK, Peghini PL, Reynolds JC, Lubensky IA, Jensen RT. Retained gastric antrum syndrome: a forgotten, treatable cause of refractory peptic ulcer disease. Dig Dis Sci 2001; 46: 610-617
99. Termanini B, Gibril F, Stewart CA, Weber HC, Jensen RT. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 61-71
100. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, editors. Endocrine Tumors of the Pancreas: Recent advances in research and management. Series: Frontiers of Gastrointestinal Research. Basel, Switzerland: S. Karger, 1995: 240-257
101. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, Jensen RT. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498-1508
102. Maton PN, Frucht H, Vinayek R, Wank SA, Gardner JD, Jensen RT. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988; 94: 294-299
103. Miller LS, Vinayek R, Frucht H, Gardner JD, Jensen RT, Maton PN. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341-346
104. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Jensen RT. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993; 17: 468-480
105. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1987; 317: 1200-1209
106. Benya RV, Metz DC, Venzon DJ, Fishbeyn VA, Strader DB, Orbuch M, Jensen RT. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med 1994; 97: 436-444
107. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807-1843
108. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644
109. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244: 410-419
110. Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7: 114-121